|
|
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for infectious, autoimmune and cardiovascular diseases. Turnover per type of income can be broken down as follows:
- Collaboration revenue (79.8%);
- Grant revenue (20.2%).
At the end of 2019, the group possessed a portfolio of 6 development candidates in clinical studies, with three in phase II and three in phase I.
Number of employees : 1 300 people.
|
|
|
| 2019 | 2020 | Delta | | Transformative Medicines | 60.21 | 100% | 803.40 | 100% | +1234.34% |
| USD in Million |
|
|
|
| 2020 | | United States | 764.53 | 95.2% |
| Rest of World | 38.87 | 4.8% |
| USD in Million |
|
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
| Stock A |
1 |
403,646,312 |
364,605,681 |
90.3% |
0 |
0.0% |
90.3% |
|
|
|
| Name | Equities | % | | Baillie Gifford & Co. | 45,883,213 |
11.4% | | Stéphane Bancel | 22,428,120 |
5.59% | | Flagship Pioneering | 20,581,016 |
5.13% | | The Vanguard Group, Inc. | 19,446,780 |
4.84% | | Robert Langer | 11,509,357 |
2.87% | | SSgA Funds Management, Inc. | 7,325,576 |
1.82% | | BlackRock Fund Advisors | 7,011,491 |
1.75% | | Fidelity Management & Research Co. LLC | 6,880,113 |
1.71% | | Coatue Management LLC | 6,140,904 |
1.53% | | Thélème Partners LLP | 6,072,056 |
1.51% |
|
|
|
|
- Nasdaq Global Select Market - Nasdaq 100 / |
|
|
|
|
| - Bloomberg Code : |
|
| - Reuters Code : |
MRNA.O |
| - Datastream Code : |
|
|
| Company contact information |
|
Moderna, Inc. 200 Square Technology MA 02139 Cambridge, Massachusetts Phone : +1 617 714 6500 Fax : +1 617 583 1998 web site : https://www.modernatx.com
|
|
|
|
Walmart says ready to administer millions of COVID-19 vaccine boosters |
Sector Other Biotechnology & Medical Research
| | 1st jan. | Capi. (M$) |
 | MODERNA, INC. | 330.15% | 184 030 |
| | | |
 | LONZA GROUP AG | 35.65% | 62 456 |
 | IQVIA HOLDINGS INC. | 45.83% | 50 064 |
 | CELLTRION, INC. | -25.49% | 31 435 |
 | SEAGEN INC. | -14.59% | 27 216 |
 | PHARMARON BEIJING CO., LTD. | 61.96% | 22 686 |
 | ALNYLAM PHARMACEUTICALS, INC. | 45.88% | 22 534 |
 | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | 77.30% | 22 326 |
 | CUREVAC N.V. | -15.30% | 21 497 |
 | ICON PUBLIC LIMITED COMPANY | 32.81% | 20 636 |
 | BIO-TECHNE CORPORATION | 60.03% | 19 859 |
 | HANGZHOU TIGERMED CONSULTING CO., LTD | -6.38% | 19 594 |
 | NOVAVAX, INC. | 132.06% | 19 274 |
 | PPD, INC. | 36.24% | 16 378 |
 | INCYTE CORPORATION | -14.85% | 16 053 |
 | QIAGEN N.V. | 5.05% | 12 629 |
 | INTELLIA THERAPEUTICS, INC. | 195.61% | 11 817 |
 | PRA HEALTH SCIENCES, INC. | 0.00% | 10 965 |
 | BACHEM HOLDING AG | 78.26% | 10 752 |
 | SYNEOS HEALTH, INC. | 38.57% | 9 770 |
 | GENSCRIPT BIOTECH CORPORATION | 201.86% | 9 678 |
Connections : Moderna, Inc.
|